Tumor-Agnostic Therapies and the Future of HER2 in Oncology

Labcorp, Rebecca Previs, Heidi Ko, HER2, NGS, precision oncology, tumor agnostic, breast cancer, gastric cancer, biomarker, ERBB2, IHC, FISH, biomarker

What tumor-agnostic approvals mean for HER2, NGS, and precision oncology — and how they’re changing treatment across cancer types.

Jun 8^th • 20 mins listen

Rethinking How We Track and Treat Cancer

Labcorp, Rebecca Previs, Michelle Green, genomics, ASCO, HER2, HER3, MRD, breast cancer, antibody drug conjugate, ADC, breast cancer, lung cancer, ctDNA, biomarker

HER2, HER3, and MRD: Drs. Previs and Green break down ASCO highlights and what they mean for the future of cancer diagnostics.

Jul 13^th • 19 mins listen

Navigating the Future of CDXs in Oncology

Rebecca Previs, Dawn McHugh, Labcorp, precision oncology, companion diagnostics, CDx, biomarker, precision medicine

CDX expert Dawn McHugh joins Dr. Rebecca Previs to unpack the role of companion diagnostics in precision oncology and the future of cancer care.

Feb 18^th • 26 mins listen

Season 1, Episode 23: Revolutionizing Cancer Treatment with Paul Romness

Welcome back to the Pharmaverse, where we speak to the greatest voices in Pharma, to learn from their leadership and incredible careers! In this episode of the Pharmaverse podcast, host Michael Pietrack interviews Paul Romness, CEO of OS Therapies. The conversation delves into the inspiring sto…

Nov 18^th • 25 mins listen